Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

Item
http://www.wikidata.org/entity/Q35610564
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trialsDownregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancerCell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.Precision medicine for metastatic breast cancer--limitations and solutions.Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patientsPredictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.Adjuvant trastuzumab: a 10-year overview of its benefit.Trastuzumab-associated cardiac events in the Persephone trial.Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.Major milestones in translational oncology.The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis.Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded studyCross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer
P2860

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

Item
http://www.wikidata.org/entity/Q35610564
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
@ast
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
@en
type
label
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
@ast
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
@en
prefLabel
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
@ast
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698